Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A recent market piece argued that Pfizer, long a bellwether in large-scale drug development and manufacturing, may fit investors’ screens for cheaper, income-oriented stocks, even as the sector continues to face ongoing pressure points.
THE APEX TIMES
THE APEX TIMES
The health insurer’s stock is up sharply over the past year, while a fresh look at its valuation metrics points to a more complicated picture than a simple bargain call.
THE APEX TIMES
A drop of nearly 1 million Medicare Advantage members was highlighted in UnitedHealth Group’s latest reporting, yet the market reaction suggests shareholders are weighing offsetting factors rather than treating the loss as a business derailment.
THE APEX TIMES
A recent analysis frames the debate around CVS Health shares as a question of valuation relative to expected earnings two years from now, not the current headline price.
THE APEX TIMES
A Yahoo Finance market recap pointed to several high-profile companies making “big moves” this week, including UnitedHealth (UNH), alongside HCA Healthcare, CrowdStrike, RXO and Enovis.
THE APEX TIMES
A market note argues that a change around Wegovy could re-shape parts of the GLP-1 landscape, yet Eli Lilly is not written out of the obesity-drug race.
THE APEX TIMES
The Eli Lilly partner Omada has jumped more than 118% over roughly three months, according to a new market roundup, as the company appears to be working through a fresh market “base.”
THE APEX TIMES
The retailer said it has launched its first new neighborhood-focused CVS Pharmacy in Houston, a format designed to broaden access to everyday pharmacy care. CVS also indicated it intends to bring a similar rollout to additional locations.
THE APEX TIMES
Joyner argued that insurers need stronger evidence that current GLP-1 list prices will produce enough “downstream” healthcare savings to justify covering broader use for weight loss.
